LMR Partners’s Biogen BIIB Stock Holding History

LMR Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-92,500	Closed	-$23.8M	–	1001
2023 Q3	$23.8M	Buy	92,500 +67,500	+270%	+$18.1M	0.27%	89
2023 Q2	$7.12M	Buy	+25,000	New	+$7.44M	0.08%	217
2022 Q4	–	Sell	-685,300	Closed	-$183M	–	1120
2022 Q3	$183M	Buy	+685,300	New	+$146M	3.37%	1

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LMR Partners's BIIB Position: Q1 2026 in Review

LMR Partners increased its Biogen (BIIB) stake by 1,246% in Q1 2026, buying an estimated $19.8M and bringing the position to 116,131 shares worth $21.3M. The position accounts for 0.05% of the portfolio, ranked #202.

LMR Partners first reported a position in BIIB in Q2 2014 and has held it in 24 quarters since. The position peaked at $49.9M in Q2 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

LMR Partners held 116,131 shares of Biogen worth $21.3M as of Q1 2026.
LMR Partners bought 107,501 Biogen shares in Q1 2026, an estimated $19.8M.
Biogen made up 0.05% of LMR Partners's portfolio in Q1 2026, its #202 holding.
LMR Partners first reported a position in Biogen in Q2 2014 and has held it in 24 quarters since.
LMR Partners's Biogen position peaked at $49.9M in Q2 2023.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.